التفاصيل البيبلوغرافية
| العنوان: |
Cardiovascular and renal outcomes with empagliflozin in heart failure |
| المؤلفون: |
Packer M., Anker S. D., Butler J., Filippatos G., Pocock S. J., Carson P., Januzzi J., Verma S., Tsutsui H., Brueckmann M., Jamal W., Kimura K., Schnee J., Zeller C., Cotton D., Bocchi E., Bohm M., Choi D. -J., Chopra V., Chuquiure E., Giannetti N., Janssens S., Zhang J., Gonzalez Juanatey J. R., Kaul S., Brunner-La Rocca H. -P., Merkely B., Nicholls S. J., Perrone S., Pina I., Ponikowski P., Sattar N., Senni M., Seronde M. -F., Spinar J., Squire I., Taddei S., Wanner C., Zannad F., EMPEROR-Reduced Trial Investigators: D Aizenberg, L Cartasegna, H Colombo, M Fernandez Moutin, J Glenny, C Alvarez Lorio, D Anauch, R Campos, A Facta, A Fernandez, R Ahuad Guerrero, L Lobo Márquez, R A Leon de la Fuente, M Mansilla, M Hominal, E Hasbani, M Najenson, H Luquez, L Guzman, H Sessa, M Amuchástegui, O Salomone, E Perna, D Piskorz, M Sicer, D Perez de Arenaza, C Zaidman, S Nani, C Poy, J Resk, R Villarreal, C Majul, F Colombo Berra, T Smith Casabella, G Carnero, A Caccavo, M Berli, N Budassi, J Bono, A Alvarisqueta, J Amerena, K Kostner, A Hamilton, A Begg, D Colquhoun, A Sverdlov, G Vaddadi, J Wong, J Coller, D Prior, A Friart, A Leone, S Janssens, G Vervoort, P Timmermans, T Sarens, H Vandekerckhove, P Van De Borne, F Chenot, J De Sutter, A Z Maria Middelares, E De Vuyst, P Debonnaire, M Dupont, O Pereira Dutra, L H Canani, M da Consolação Vieira Moreira, W de Souza, L M Backes, L Maia, E R Manenti, F Villaça Guimarães Filho, T Franco Hirakawa, L A Saliba, F C Neuenschwander, C A de Freitas Zerbini, G Gonçalves, Y Gonçalves Mello, J Ascenção de Souza, L Beck da Silva Neto, E A Bocchi, J Da Silveira, M Hernandes, H C Finimundi, C R Sampaio, E Vasconcellos, F J Neves Mancuso, M M Noya Rabelo, M Rodrigues Bacci, F Santos, M Vidotti, M V Simões, R Preto, F L Gomes, C Vieira Nascimento, D Precoma, J A Ribas Fortes, P E Leães, J F Kerr Saraiva, F A Alves da Costa, G Reis, S Zieroth, D Dion, D Savard, R Bourgeois, C Constance, K Anderson, S Verma, M Leblanc, D Yung, E Swiggum, L Pliamm, B Tyrrell, T Huynh, J Spiegelman, N Giannetti, J Lavoie, M Hartleib, R Bhargava, L Straatman, S Virani, A Costa-Vitali, L Hill, M Heffernan, Y Khaykin, J Ricci, A Zhai, B Lubelsky, M Toma, L Yao, L Noronha, M Babapulle, A Pandey, G Curnew, J Berlingieri, S Kouz, E Lonn, R Chehayeb, Y Zheng, Y Sun, Z Fan, X Han, X Jiang, Q Tang, Z Zheng, J Zhang, Y Zhang, A Shen, J Yu, J Ye, Y Yao, J Yan, X Xu, J Ma, Y Li, S Li, S Lu, X Kong, G Yang, Z Yao, Y Pan, X Guo, Z Sun, Y Dong, D Peng, Z Yuan, J Lin, O Jerabek, H Burianova, T Fiala, J Hubac, O Ludka, P Vodnansky, K Zeman, D Foldyna, J Krupicka, L Busak, M Radvan, Z Vomacka, R Prosecky, R Cifkova, V Durdil, J Vesely, J Vaclavik, P Cervinka, A Linhart, T Brabec, R Miklik, E Bonnefoy Cudraz, A Jobbe Duval, D Tomasevic, G Habib, R Isnard, F Picard, P Khanoyan, J Dubois-Rande, M Galinier, F Roubille, J Alexandre, D Babuty, N Delarche, M Seronde, J Berneau, N Girerd, H Bourhaial, H Olbrich, S Genth-Zotz, E Kemala, B Lemke, M Böhm, S Schellong, W Rieker, M Faghih, A Birkenfeld, A Begemann, A Ghanem, A Ujeyl, S von Haehling, H Ince, T Dorsel, J Bauersachs, M Prull, H Darius, A Wilke, J Sauter, N Frey, C P Schulze, W König, L Maier, N Proskynitopoulos, H Ebert, H Sarnighausen, H Düngen, M Licka, N Marx, C Stellbrink, B Winkelmann, N Menck, L Koenyves, F Lakatos, A Matoltsy, E Noori, P Andrassy, S Kancz, G Simon, T Sydo, A Vorobcsuk, B Merkely, R Gabor Kiss, I Szakal, N Laszlo, T Barany, A Nagy, E Szolnoki, V Chopra, V Rastogi, B Shah, A Mullasari, J Shankar, V Mehta, A Oomman, T Nadu, U Kaul, S Komarlu, D Kahali, A Bhagwat, V Vijan, N Kamalakar Ghaisas, A Mehta, Y Kothari, S Taddei, M Scherillo, V Zacà, S Genovese, A Salvioni, A Fucili, F Fedele, F Cosmi, M Volpe, M Senni, C Mazzone, G Esposito, M Doi, H Yamamoto, S Sakagami, S Oishi, Y Yasaka, H Tsuboi, Y Fujino, S Matsuoka, Y Watanabe, T Himi, T Ide, M Ichikawa, Y Kijima, T Koga, S Yuda, K Fukui, T Kubota, M Manita, H Fujinaga, T Matsumura, Y Fukumoto, Y Kawai, G Hiasa, Y Kazatani, M Mori, A Ogimoto, M Inoko, M Oguri, M Kinoshita, K Okuhara, N Watanabe, Y Ono, K Otomo, Y Sato, T Matsunaga, A Takaishi, N Miyagi, H Uehara, H Takaishi, M Yagi, M Arikawa, T Hashizume, T Koizumi, K Nakayama, S Taguchi, M Nanasato, Y Yoshida, S Tsujiyama, T Nakamura, K Oku, M Shimizu, M Suwa, Y Momiyama, H Sugiyama, K Kobayashi, S Inoue, T Kadokami, K Maeno, K Kawamitsu, Y Maruyama, A Nakata, Y Shibata, A Wada, H Urata, T Kataoka, T Matsumoto, N Takahashi, M Imamaki, T Yoshitama, T Saito, H Sekino, Y Furutani, M Koda, T Shinozaki, K Hirabayashi, R Tsunoda, K Yonezawa, H Hori, G Llamas Esperon, J Illescas Díaz, P Fajardo, J Almeida Alvarado, A Bazzoni Ruiz, I Lopez Alcocer, L Valle Molina, C Hernandez Herrera, C Calvo Vargas, F G Padilla Padilla, I Rodriguez Briones, E Chuquiure Valenzuela, M Aguilera Real, J Carrillo Calvillo, M Alpizar Salaza, J Cervantes Escárcega, R Velasco Sanchez, N Al-Windy, L van Heerebeek, L Bellersen, H Brunner-La Rocca, J Post, G C M Linssen, M van de Wetering, R Peters, R van Stralen, R Groutars, P Smits, A Yilmaz, W E M Kok, P Van der Meer, P Dijkmans, R Troquay, A P van Alem, R Van de Wal, L Handoko, I C D Westendorp, P F M M van Bergen, B J W M Rensing, P Hoogslag, B Kietselaer, J A Kragten, F R den Hartog, L Danilowicz-Szymanowicz, G Raczak, W Piesiewicz, W Zmuda, W Kus, P Podolec, W Musial, G Drelich, G Kania, P Miekus, S Mazur, A Janik, J Spyra, J Peruga, P Balsam, B Krakowiak, J Szachniewicz, M Ginel, J Grzybowski, P Wojewoda, A Kalinka, A Zurakowski, R Koc, M Debinski, W Fil, M Kujawiak, J Forys, M Kasprzak, M Krol, P Michalski, E Mirek-Bryniarska, K Radwan, G Skonieczny, K Stania, G Skoczylas, A Madej, J Jurowiecki, B Firek, B Wozakowska-Kaplon, K Cymerman, H Cho, J Oh Na, B Yoo, J Choi, J Shin, M Cho, D Choi, S Hwan Han, J Jeong, J Kim, S Min Kang, D Kim, M Hyun Kim, J López-Sendón, L de la Fuente Galán, J Delgado Jiménez, N Manito Lorite, M Pérez de Juan Romero, F Cereto Castro, J González Juanatey, J Gómez, M Sanmartín Fernández, X Garcia-Moll Marimon, D Pascual Figal, R Bover Freire, M Saxena, Z Yousef, C Clifford, C Arden, A Bakhai, I Squire, G Jenkins, C Travill, D Price, J Neutel, K Adams, P Balfour, A Djamson, P Duncan, M Hong, S Woodhouse, R MacNevin, B Rama, C Broome-Webster, S Kindsvater, M Barettella, S Pinney, A Cohen, K Vora, K Challappa, S West, S Baum, J Cox, S Jani, A Karim, A Akhtar, R Goldberg, Z Bhatti, M Budoff, E Bush, A Potler, B Ellis, J Dy, J Fialkow, R Sangrigoli, K Ferdinand, C East, S Falkowski, S Donahoe, R Ebrahimi, G Kline, B Harris, R Khouzam, N Jaffrani, N Jarmukli, N Kazemi, M Koren, K Friedman, W Herzog, D Cheung, M Grover-McKay, P Hauptman, D Mikhalkova, S Khouri, F McGrew, P McCullough, R Littlefield, P Bradley, B McLaurin, S Lupovitch, I Labin, V Rao, M Leithe, N Lewis, D Lombardo, S Mahal, V Malhotra, I Dauber, A Banerjee, J Needell, G Miller, L Paladino, K Munuswamy, M Nanna, E McMillan, M Mumma, M Napoli, W Nelson, T O'Brien, A Adlakha, A Onwuanyi, H Serota, J Schmedtje, A Paraschos, R Potu, C Sai-Sudhakar, A Sauer, P Shah, H Skopicki, H Bui, K Carr, G Stevens, N Tahirkheli, J Tallaj, K Yousuf, B Trichon, J Welker, A Vest, X Wang, R Abadier, S Dunlap, N Weintraub, A Malik, P Kotha, V Zaha, G Kim, N Uriel, T Greene, A Salacata, R Arora, R Gazmuri, J Kobayashi, B Iteld, R Dab, Z Mirza, V Marques, M Nallasivan, H Saint-Jacques, K Barringhaus, J Contreras, A Gupta, S Koneru, V Nguyen |
| المساهمون: |
M., Packer, S. D., Anker, J., Butler, G., Filippato, S. J., Pocock, P., Carson, J., Januzzi, S., Verma, H., Tsutsui, M., Brueckmann, W., Jamal, K., Kimura, J., Schnee, C., Zeller, D., Cotton, E., Bocchi, M., Bohm, D. -J., Choi, V., Chopra, E., Chuquiure, N., Giannetti, S., Janssen, J., Zhang, J. R., Gonzalez Juanatey, S., Kaul, H. -P., Brunner-La Rocca, B., Merkely, S. J., Nicholl, S., Perrone, I., Pina, P., Ponikowski, N., Sattar, M., Senni, M. -F., Seronde, J., Spinar, I., Squire, S., Taddei, C., Wanner, F., Zannad, D Aizenberg, EMPEROR-Reduced Trial Investigators, Cartasegna, L, Colombo, H, Fernandez Moutin, M, Glenny, J, Alvarez Lorio, C, Anauch, D, Campos, R, Facta, A, Fernandez, A, Ahuad Guerrero, R, Lobo Márquez, L, A Leon de la Fuente, R, Mansilla, M, Hominal, M, Hasbani, E, Najenson, M, Luquez, H, Guzman, L, Sessa, H, Amuchástegui, M, Salomone, O, Perna, E, Piskorz, D, Sicer, M, Perez de Arenaza, D, Zaidman, C, Nani, S, Poy, C, Resk, J, Villarreal, R, Majul, C, Colombo Berra, F, Smith Casabella, T, Carnero, G, Caccavo, A, Berli, M, Budassi, N, Bono, J, Alvarisqueta, A, Amerena, J, Kostner, K, Hamilton, A, Begg, A, Colquhoun, D, Sverdlov, A, Vaddadi, G, Wong, J, Coller, J, Prior, D, Friart, A, Leone, A, Janssens, S, Vervoort, G, Timmermans, P, Sarens, T, Vandekerckhove, H, Van De Borne, P, Chenot, F, De Sutter, J, Z Maria Middelares, A |
| بيانات النشر: |
Massachussetts Medical Society
WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA |
| سنة النشر: |
2020 |
| المجموعة: |
Sapienza Università di Roma: CINECA IRIS |
| مصطلحات موضوعية: |
Aged, Benzhydryl Compound, Cardiovascular Disease, Diabetes Mellitus, Type 2, Disease Progression, Double-Blind Method, Female, Glomerular Filtration Rate, Glucoside, Heart Failure, Hospitalization, Human, Male, Middle Aged, Proportional Hazards Model, Renal Insufficiency, Chronic, Sodium-Glucose Transporter 2 Inhibitor, Stroke Volume |
| الوصف: |
BACKGROUND Sodium-glucose cotransporter 2 (SGLT2) inhibitors reduce the risk of hospitalization for heart failure in patients regardless of the presence or absence of diabetes. More evidence is needed regarding the effects of these drugs in patients across the broad spectrum of heart failure, including those with a markedly reduced ejection fraction. METHODS In this double-blind trial, we randomly assigned 3730 patients with class II, III, or IV heart failure and an ejection fraction of 40% or less to receive empagliflozin (10 mg once daily) or placebo, in addition to recommended therapy. The primary outcome was a composite of cardiovascular death or hospitalization for worsening heart failure. RESULTS During a median of 16 months, a primary outcome event occurred in 361 of 1863 patients (19.4%) in the empagliflozin group and in 462 of 1867 patients (24.7%) in the placebo group (hazard ratio for cardiovascular death or hospitalization for heart failure, 0.75; 95% confidence interval [CI], 0.65 to 0.86; P<0.001). The effect of empagliflozin on the primary outcome was consistent in patients regardless of the presence or absence of diabetes. The total number of hospitalizations for heart failure was lower in the empagliflozin group than in the placebo group (hazard ratio, 0.70; 95% CI, 0.58 to 0.85; P<0.001). The annual rate of decline in the estimated glomerular filtration rate was slower in the empagliflozin group than in the placebo group (-0.55 vs. -2.28 ml per minute per 1.73 m2 of body-surface area per year, P<0.001), and empagliflozin-treated patients had a lower risk of serious renal outcomes. Uncomplicated genital tract infection was reported more frequently with empagliflozin. CONCLUSIONS Among patients receiving recommended therapy for heart failure, those in the empagliflozin group had a lower risk of cardiovascular death or hospitalization for heart failure than those in the placebo group, regardless of the presence or absence of diabetes. |
| نوع الوثيقة: |
article in journal/newspaper |
| اللغة: |
English |
| العلاقة: |
info:eu-repo/semantics/altIdentifier/pmid/32865377; info:eu-repo/semantics/altIdentifier/wos/WOS:000579622800009; volume:383; issue:15; firstpage:1413; lastpage:1424; numberofpages:12; journal:NEW ENGLAND JOURNAL OF MEDICINE; http://hdl.handle.net/11573/1526264Test; info:eu-repo/semantics/altIdentifier/scopus/2-s2.0-85090992310 |
| DOI: |
10.1056/NEJMoa2022190 |
| الإتاحة: |
https://doi.org/10.1056/NEJMoa2022190Test
http://hdl.handle.net/11573/1526264Test |
| رقم الانضمام: |
edsbas.9F59E9DE |
| قاعدة البيانات: |
BASE |
